Evidence map›Paper›PMID 35397357›Full record

ReviewThe American journal of emergency medicine2022

Clinical update on COVID-19 for the emergency and critical care clinician: Medical management.

Brit Long, Summer Chavez, Brandon M Carius, William J Brady, Stephen Y Liang, Alex Koyfman, Michael Gottlieb

Open access · greenAbstract readReview
In one paragraph

Review in The American journal of emergency medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 7 institutions in 2 countries.

Brit LongSAUSHEC, Emergency Medicine, Brooke Army Medical Center, 3551 Roger Brooke Dr, Fort Sam Houston, TX, USA. Electronic address: Brit.long@yahoo.com.
Summer ChavezDepartment of Emergency Medicine, UT Health Houston McGovern School of Medicine, 6431 Fannin Street, Houston, TX, 77030, USA. Electronic address: summer.a.chavez@gmail.com.
Brandon M Carius121 Field Hospital, Camp Humphreys, US Army, Republic of Korea. Electronic address: doccarius@gmail.com.
William J BradyDepartment of Emergency Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA. Electronic address: WB4Z@hscmail.mcc.virginia.edu.
Stephen Y LiangDivisions of Emergency Medicine and Infectious Diseases, Washington University School of Medicine, 660 S. Euclid Ave, St. Louis, MO, 63110, USA. Electronic address: syliang@wustl.edu.
Alex KoyfmanThe University of Texas Southwestern Medical Center, Department of Emergency Medicine, 5323 Harry Hines Boulevard, Dallas, TX, 75390, USA. Electronic address: akoyfman8@gmail.com.
Michael GottliebDepartment of Emergency Medicine, Rush University Medical Center, Chicago, IL, USA. Electronic address: MichaelGottliebMD@gmail.com.
Brooke Army Medical Center · USRepublic of Korea Army · KRRush University Medical Center · USThe University of Texas Health Science Center · USThe University of Texas Southwestern Medical Center · USUniversity of Virginia · USWashington University in St. Louis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCoronavirus disease of 2019 (COVID-19) has resulted in millions of cases worldwide. As the pandemic has progressed, the understanding of this disease has evolved.

objectiveThis is the second part in a series on COVID-19 updates providing a focused overview of the medical management of COVID-19 for emergency and critical care clinicians. DISCUSSION: COVID-19, caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), has resulted in significant morbidity and mortality worldwide. A variety of medical therapies have been introduced for use, including steroids, antivirals, interleukin-6 antagonists, monoclonal antibodies, and kinase inhibitors. These agents have each demonstrated utility in certain patient subsets. Prophylactic anticoagulation in admitted patients demonstrates improved outcomes. Further randomized data concerning aspirin in outpatients with COVID-19 are needed. Any beneficial impact of other therapies, such as colchicine, convalescent plasma, famotidine, ivermectin, and vitamins and minerals is not present in reliable medical literature. In addition, chloroquine and hydroxychloroquine are not recommended.

conclusionThis review provides a focused update of the medical management of COVID-19 for emergency and critical care clinicians to help improve care for these patients.

Indexed as

COVID-19Antiviral AgentsCOVID-19 SerotherapyCritical CareHumansImmunization, PassivePandemicsSARS-CoV-2Antiviral AgentsCoronavirus-2019COVID-19SARS-CoV-2Severe acute respiratory syndrome coronavirus 2

Identifiers

PMID35397357
PMCPMC8956349
OpenAlexW4220901603

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.